Cardio Diagnostics (NASDAQ:CDIOW) versus Enlivex Therapeutics (NASDAQ:ENLV) Head to Head Analysis

Enlivex Therapeutics (NASDAQ:ENLV) and Cardio Diagnostics (NASDAQ:CDIOW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Enlivex Therapeutics and Cardio Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1	1	1	1	2.50
Cardio Diagnostics	0	0	0	0	0.00

Enlivex Therapeutics presently has a consensus price target of $247.50, indicating a potential upside of 16,182.89%. Given Enlivex Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Cardio Diagnostics.

Valuation & Earnings

This table compares Enlivex Therapeutics and Cardio Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($8.25)	-0.18
Cardio Diagnostics	$14,450.00	N/A	N/A	N/A	N/A

Enlivex Therapeutics has higher earnings, but lower revenue than Cardio Diagnostics.

Insider and Institutional Ownership

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Enlivex Therapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Cardio Diagnostics	N/A	N/A	N/A

Summary

Enlivex Therapeutics beats Cardio Diagnostics on 8 of the 9 factors compared between the two stocks.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.